These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 32526750)

  • 1. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and Emerging Immunotherapies for Systemic AL Amyloidosis.
    Moreno V; Saba L; Tama-Shekan S; Chaulagain CP
    Discov Med; 2024 Sep; 36(188):1761-1771. PubMed ID: 39327239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in the Diagnosis, Risk Stratification, and Management of Systemic Light-Chain Amyloidosis.
    Vaxman I; Gertz M
    Acta Haematol; 2019; 141(2):93-106. PubMed ID: 30650422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Blood; 2020 Dec; 136(23):2620-2627. PubMed ID: 33270858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2022 Jun; 97(6):818-829. PubMed ID: 35429180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
    Blair HA
    Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging drugs for the treatment of light chain amyloidosis.
    Chakraborty R; Lentzsch S
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements and future trends of immunotherapy in light-chain amyloidosis.
    Mahadevia H; Ponvilawan B; Sharma P; Al-Obaidi A; Qasim H; Koyi J; Anwer F; Raza S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103917. PubMed ID: 36696931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conventional Therapy for Amyloid Light-Chain Amyloidosis.
    Milani P; Palladini G
    Acta Haematol; 2020; 143(4):365-372. PubMed ID: 32353854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2024 Feb; 99(2):309-324. PubMed ID: 38095141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside.
    Basset M; Nuvolone M; Palladini G; Merlini G
    Expert Rev Hematol; 2020 Sep; 13(9):1003-1015. PubMed ID: 32721177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supportive Care in AL Amyloidosis.
    Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
    Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
    Sanchorawala V
    Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of novel therapies in the treatment of light chain amyloidosis.
    Varga C; Titus SE; Toskic D; Comenzo RL
    Blood Rev; 2019 Sep; 37():100581. PubMed ID: 31167719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.